Asia Pacific Patient Controlled Injectors Market

Market Introduction

Patient controlled Injectors are subcutaneous drug delivery systems that adhere to the body and administer larger volumes (more than 2 mL) of a drug over an extended period. With the use of patient-controlled injectors, dosing errors, microbial contamination risks, and needle stick injuries can be avoided that are caused during parenteral drug administration using injections. In the last few years, the pharmaceutical industry has witnessed the introduction of several innovative interventions for the treatment of various chronic diseases.

Market Overview and Dynamics

The Asia Pacific patient controlled injectors market is expected to reach US$ 1,637.74 million by 2027 from US$ 621.47 million in 2019. The market is anticipated to grow at a CAGR of 12.9% during 2019–2027. The increasing chronic diseases prevalence, and conventional drug delivery system limitations are the major factors expected to boost the growth of the patient controlled injectors market in Asia Pacific. However, the market is likely to get impacted by the risk factor such as lack of adoption of patient controlled injectors in emerging countries during the forecast period.

Key Market Segments

In terms of products, the electronic injector segment accounted for the largest share of the Asia Pacific patient controlled injectors market in 2019. In terms of application, the cancer treatment segment accounted for the largest share of the Asia Pacific patient controlled injectors market in 2019. In terms of distribution channel, the hospital pharmacies segment accounted for the largest share of the Asia Pacific patient controlled injectors market in 2019.

Major Sources and Companies Listed

Several major primary and secondary sources associated with the Asia Pacific patient controlled injectors market report are the World Health Organization (WHO), Global Burden of Disease (GBD), The Indian Council for Medical Research, Institute for Health Metrics and Evaluation, International Diabetes Federation (IDF), Australian Bureau of Statistics, Health Ministry of Japan and others.

Reasons to buy report

• It provides understanding of the Asia Pacific, patient controlled injectors market landscape and identifies patient controlled injectors market segments that are most likely to guarantee a strong return.
• It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the Asia Pacific patient controlled injectors market.
• It helps efficiently plan merger and acquisition, and partnership deals in the patient controlled injectors market by identifying market segments with the most promising probable sales
• It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of patient controlled injectors market performance of various segments pertaining to the Asia Pacific patient controlled injectors market.
• It provides patient controlled injectors market revenue forecast of the market based on various segments for the period from 2019 to 2027.

ASIA PACIFIC PATIENT CONTROLLED INJECTORS MARKET SEGMENTATION

By Products

• Electronic Wearable Injector
• Mechanical Wearable Injector
• Infusion Pumps

By Application

• Cancer Treatment
• Auto-immune Treatment
• Blood Disorders Treatment
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Mail Order Pharmacies

By Country

• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific

Company Profiles

• Johnson and Johnson Services, Inc.
• Sensile Medical AG (Gerresheimer AG)
• F. HOFFMANN-LA ROCHE LTD
• Ypsomed AG
• Westbourne Medical Limited

Asia Pacific Patient Controlled Injectors Market Strategic Insights

Asia Pacific Patient Controlled Injectors Market Segmentation Analysis

Asia Pacific Patient Controlled Injectors Market Report Highlights

Asia Pacific Patient Controlled Injectors Report Scope

Asia Pacific Patient Controlled Injectors Market Country and Regional Insights